Sharps Technology (STSS) soared nearly 60% this morning after revealing plans of putting Solana (SOLUSD), the native digital asset of the Solana blockchain, on its balance sheet. 

On Monday, the company announced a $400 million PIPE offering to “establish the largest Solana digital asset treasury,” which the management believes “will set STSS up for success.”

Despite today’s massive rally, Sharps Technology stock is trading only at a fraction of the price at which it started this year. 

SOL Strategy Could Prove a Tailwind for STSS Stock

Sharps Technology’s decision to raise $400 million and invest in SOL effectively couples its stock price to one of the fastest-growing blockchain ecosystems in the world. 

The announcement could prove significantly positive for STSS shares over the long term given it positions them to capitalize on Solana’s strong developer activity, high transaction throughput, and staking yield potential. 

Moreover, the strategic pivot toward digital asset treasury strategy could attract crypto enthusiasts and institutional capital as well, which may translate to sustained upside for STSS stock. 

This diversification will help Sharps Technology reposition itself beyond its core medical device business, offering new growth narrative and boosting investor sentiment.

As blockchain adoption continues to accelerate across industries, the company’s SOL holdings could also appreciate and generate passive income for it through staking. 

Why STSS Shares Remain a Speculative Bet in 2025

While the likes of MicroStrategy (MSTR) have established that digital asset treasury strategies can succeed, caution is still warranted in buying Sharps Technology stock at current levels. 

Why? Because it’s a non-profitable business that’s barely generating any meaningful revenue. In fact, the Nasdaq-listed firm lacks a consistent earnings history, and its pivot from medical devices to crypto is untested. 

More importantly, STSS stock receives no coverage from Wall Street analysts as tracked by Barchart, leaving investors without professional guidance or valuation benchmarks.  Sure, the PIPE offering boosts liquidity, but it dilutes existing shareholders as well. 

In short, without proven execution in either healthcare or blockchain, STSS shares remain a high-risk speculative bet rather than a sound investment for the second half of 2025.